Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 223 clinical trials
Featured trial
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

  • 142 views
  • 03 Oct, 2019
  • 1 location
Featured trial
C3711005

The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1 dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced elevations in serum triglycerides. The study has a 2-part design with sequential conduct of Part 1 and Part 2 …

  • 804 views
  • 10 Jan, 2022
  • 3 locations
Featured trial
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

  • 1366 views
  • 01 Jul, 2022
  • 44 locations
Featured trial
Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)

Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)

  • 1556 views
  • 23 Nov, 2020
  • 1 location
Featured trial
TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

  • 426 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • 1167 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • 446 views
  • 25 Mar, 2021
  • 1 location
Featured trial
AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • 492 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS

The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis and explored in subjects with NASH and Stage 4 fibrosis. This study is designed to assess response to treatment on measures …

  • 58 views
  • 23 Nov, 2020
  • 1 location
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to …

  • 73 views
  • 11 Mar, 2022
  • 226 locations